Preoperative Evaluation of Pulmonary Hypertension in Lung Transplant Candidates: Echocardiography Versus Right Heart Catheterization

Tal Abu

The Hebrew University of Jerusalem

Amos Levi

Rabin Medical Center – Beilinson Hospital

David Hasdai

Rabin Medical Center – Beilinson Hospital

Mordechai R. Kramer

Rabin Medical Center – Beilinson Hospital

Tamir Bental

Rabin Medical Center – Beilinson Hospital

Tali Bdolah-Abram

The Hebrew University of Jerusalem

Arthur Shyovich

Rabin Medical Center – Beilinson Hospital

Abed Samara

Rabin Medical Center – Beilinson Hospital

Hana Vaknin-Assa

Rabin Medical Center – Beilinson Hospital

Leor Perl

Rabin Medical Center – Beilinson Hospital

Dror Rosengarten

Rabin Medical Center – Beilinson Hospital

Yaron Shapira

Rabin Medical Center – Beilinson Hospital

Ran Kornowski

Rabin Medical Center – Beilinson Hospital

Keren Skalsky (✉ kerens@clalit.org.il)

Rabin Medical Center – Beilinson Hospital

Keywords: Lung transplant, Right heart catheterization, Pulmonary hypertension

Posted Date: November 19th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-1072420/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Cardiovascular Disorders on February 16th, 2022. See the published version at <https://doi.org/10.1186/s12872-022-02495-y>.

Abstract

Background - Right heart catheterization (RHC) and echocardiography are both routinely used for pulmonary artery systolic pressure (PASP) assessment in lung transplantation (LT) candidates, although this is not mandated by current guidelines. We aimed to explore the correlation between PASP estimated by echocardiography to that measured by RHC, in this population in order to assess the necessity of RHC.

Methods - From a retrospective registry of 393 LT candidates undergoing RHC and echocardiography during 2015-2019, patients were assessed for the presence of pulmonary hypertension (PH), defined as mean pulmonary artery pressure (mPAP) above 20 mmHg, according to two methods – echocardiography and RHC. The primary outcome was the correlation between the PASP estimated by echocardiography to that measured by RHC. Secondary outcomes were the prediction value of the echocardiographic evaluation and its accuracy.

Results - The mean value of PASP estimated by echocardiography was 49.5 ± 20.0 mmHg, compared to 42.5 ± 18.0 mmHg measured by RHC. The correlation between the two measurements was moderate (Pearson's correlation: $r=0.609$, $p<0.01$). Echocardiography PASP measurements were moderately discriminative to diagnose PH, with an area under the curve (AUC) of 0.72 (95% CI 0.66-0.76). Echocardiographic overestimation of PASP of more than 10 mmHg was found in 35.0% of the patients, and underestimation was found in 11.6% of the patients.

Conclusion - In the pre-surgical evaluation of LT candidates, echocardiographic estimation of PASP had moderate correlation and limited accuracy compared to the PASP measured by RHC. We thus recommend performing routine RHC to all LT candidates, regardless of the echocardiographic estimation of PASP.

Introduction

Lung transplant (LT) is a life-saving procedure for advanced stage of lung disease¹. Pulmonary hypertension (PH), defined as mean pulmonary artery pressure (mPAP) above 20 mmHg², is common in those patients and is important to recognize prior to transplant. Its diagnosis gives priority on the waiting list for lung transplantation according to Lung Allocation Score³ and may lead to initiation of specific drug therapy, aiming to lower it before the transplant operation^{4,5}. Moreover, elevated pulmonary pressure is a predictor of early death post transplantation⁶⁻⁸.

Right heart catheterization (RHC) is the gold standard for measuring pulmonary artery systolic pressure (PASP), mean pulmonary artery pressure (mPAP) and other cardiac hemodynamic parameters⁹⁻¹¹. When performed in an experienced center, RHC in patients with pulmonary arterial hypertension (PAH) is associated with 1.1% morbidity and 0.055% mortality complication rate¹². Echocardiography is an acceptable non-invasive alternative for measuring PASP. It provides an estimation of PASP, by adding the

regurgitant flow on continuous-wave Doppler over the tricuspid valve to the estimated right atrial pressure (RAP)^{10,11,13,14}.

Whether non-invasive echocardiography is accurate enough to forego RHC and its complications in LT candidates is debatable. The Pulmonary Council of the International Society for Heart and Lung Transplantation (ISHLT) consensus document on LT candidates published in 2015 states that echocardiography is recommended in all LT candidates in their preoperative evaluation¹⁵. The ESC guidelines for the diagnosis and treatment of PH states that an echocardiography should be used as a screening tool for PH in all patients with suspected elevated PAH, but when treatment of PAH is being considered, echocardiography alone is not sufficient to support a treatment decision, and RHC is required⁵. In practice, both tests, echocardiography and RHC, are routinely used in order to estimate and measure PASP of LT candidates in many centers worldwide. We aimed herein to examine the correlation between the estimated PASP obtained by echocardiography and PASP measured by RHC in a large contemporary cohort of LT candidates.

Methods

This observational study is based on a retrospectively cohort of 461 LT candidates evaluated for transplant by RHC at two campuses of Rabin Medical Center from January 2015 through December 2019. Of these, we analyzed 393 patients who underwent echocardiography within one year from RHC. For each LT candidate, we collected additional data about demographics (age and gender), medical history (e.g., Diabetic mellitus – DM, Hypertension – HTN, smoking, COPD, Chronic kidney disease – CKD, Coronary artery disease – CAD, Hyperlipidemia, Body mass index – BMI and lung failure etiology. Full echocardiographic assessment including left ventricle (LV) systolic function, right ventricular function and valvular disease were recorded. Right atrial pressure was assessed according to the inferior vena cava (IVC) size and collapsibility (>2.1 cm, collapse $< 50\%$: RAP 15 mm Hg)¹⁶. PASP was assessed by adding the trans tricuspid pressure gradient during systole (estimated by applying the Bernoulli equation on the measured maximal tricuspid regurgitant jet velocity with continuous wave doppler) to the estimated right atrial pressure^{17,18}. RHC was performed via the venous femoral or cubital fossa access using a 6 – 7 FR swan ganz catheter. Direct hemodynamic measurements of the right sided chambers as well as the pulmonary artery pressure were performed. Pulmonary capillary wedge pressure (PCWP) was measured by wedging the swan ganz catheter with an inflated balloon into a small pulmonary arterial branch. Cardiac output was calculated according to the Fick principle, using the arterial-venous oxygen content difference and the blood hemoglobin level.

The study protocol and data collection was approved by Rabin Medical Center's human research committee, according to the ethical guidelines of the 1975 declaration of Helsinki. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of the study.

The primary endpoint of the study was the correlation between PASP estimated by echocardiography and PASP measured by RHC. Secondary endpoints were the prediction value of the echocardiographic

assessment of PH and its accuracy. To examine the relationship between two quantitative variables, the Pearson correlation coefficient and the equation of the regression line were calculated. Comparison of quantitative variables was performed using the two-sample t-test for normally distributed variables or the Wilcoxon test for non-normally distributed variables. The association between two categorical variables was tested using either the Chi-Square test or the Fisher's exact test as appropriate. ROC curves were plotted to study the diagnostic performance of echocardiography based PASP to diagnose PH (defined by RHC mPAP > 20 mmHg) and severely elevated pulmonary pressure (RHC mPAP > 40 mmHg). For each ROC curve, maximal Youden's index was calculated to define the optimal cut-off point to distinguish between patients with or without PH. The Bland-Altman method was used to plot the difference in PASP measurements for each patient (RHC PASP measurement minus estimated PASP per echocardiogram) against the mean of the two measurements. Statistical analysis was performed using IBM SPSS statistics software (version 25). A p value ≤ 0.05 was considered statistically significant for all analyses.

Results

TR jet, allowing estimation of the PASP during echocardiography, was recognized in 351 out of 393 LT candidates undergoing RHC (89.1%). Patients were predominantly males (63.6%) with a mean age of 61.5 ± 8.3 years (Table 1). ILD was the most common primary lung disease in more than half of the patients, and COPD was the next most common diagnosis (Supplementary Table 1). Among these patients, approximately a third had diabetes mellitus and hypertension, more than a half were current or former smokers and almost a half were overweight or obese. History of CAD was documented in approximately a quarter of the patients (Table 1). The great majority of patients had good LV systolic function (ejection fraction (EF) >55%) as estimated by echocardiography. Heart failure with reduced EF ($\leq 55\%$) was recorded in a minority of patients, with only 1.6% patients with EF <40%. 46 candidates (11.7%) had RV dysfunction (Table 2). The average PASP estimated by echocardiography was 49.5 ± 20.0 mmHg.

Table 1
– Baseline characteristics of patients

		All patients; N=393
Age, mean (years)		61.5±8.3
Male gender (%)		63.6
Diabetes (%)		35.4
Hypertension (%)		35.1
Hyperlipidemia (%)		36.9
Chronic kidney disease (%)		7.1
Current smoking (%)		37.9
Past smoking (%)		18.3
BMI, mean		26.2±5.6
BMI categories (%)	Underweight BMI≤18	3.8
	Normal 18<BMI≤25	27.2
	Overweight 25<BMI<30	20.6
	Obese BMI≥30	21.6
CAD history (%)		23.9
*BMI – Body mass index, CAD – Chronic artery disease.		

Table 2
– Right heart catheterization and echocardiographic data

	RHC;	Echocardiography;	P value
Estimated EF, mean (%)	Not recorded	59.1±5.3	
RV dysfunction (%)		11.7	
Measurable TR (%)		89.1	
RA pressure, mean (mmHg)	5.1±4.6	6.0±3.2	0.89
PAP, mean (mmHg)	25.9±11.5	Not recorded	
PA sys, mean (mmHg)	42.5±18.0	49.5±20.0	<0.001
PCWP, mean (mmHg)	9.8±6.1	Not recorded	
PVR, mean (mmHg)	4.2±3.5		
CO, mean (L/min)	4.4±1.4		
CI, mean (L/min/m ²)	2.5±0.8		
* CO – Cardiac output, CI – Cardiac index, EF – Ejection fraction, PA – Pulmonary artery, PAP - Pulmonary arterial pressure, PCWP – Pulmonary capillary wedge pressure, PVR – Pulmonary vascular resistance, TR – Tricuspid regurgitation, RA – Right atrium, RHC – Right heart catheterization, RV – Right ventricle			

Pulmonary hypertension (mPAP>20 mmHg) as measured by RHC was recorded in 251 patients (63.9%). The mean value of mPAP measured by RHC was 25.9±11.5 mmHg and mean PASP was 42.5±18.0 mmHg. Pulmonary vascular resistance (PVR) was elevated, with a mean value of 4.2±3.5 Wood units. Mean PCWP was not elevated and the average cardiac output (CO) and cardiac index (CI) were both within the normal range (Table 2). Patients who had elevated pulmonary pressure were younger with a mean age 59.7 years vs. 62.2 years, P=0.021, and tended to have RV dysfunction (28.7%, p<0.001). No other variables were found to be associated with elevated pulmonary pressure. The mean time interval between the echocardiography and RHC was 25±372 days, and 78.3% of the patients have completed both tests within 90 days.

When comparing the two methods for PASP estimation and measurement, we found the estimated PASP to be higher than that measured by RHC – estimated PASP of 49.5±20.0 mmHg versus PASP absolute measurement of 42.5±18.0 mmHg (p<0.001). A moderate correlation between the two values was found according to Pearson's correlation: r=0.609, p<0.01 (Figure 1). The estimated PASP measured by echocardiography was significantly higher among those with confirmed diagnosis of PH (RHC mPAP >20 mmHg) compared to those with pulmonary normo-tension; mean estimated PASP 54.6±21.0mmHg versus 40.5±14.3mmHg, p <0.001 (Figure 2). The prediction value of echocardiography to diagnose PH was assessed using ROC curve, with an area under the curve (AUC) of 0.72 (95% CI 0.66-0.76). The optimal echo derived PASP cutoff value to diagnose pulmonary hypertension was 40 mmHg (at the point

of maximal Youden's index) with sensitivity of 0.73 and specificity of 0.59 (Figure 3a). When examining the prediction value to diagnose severely elevated pulmonary pressure (mPAP above 40 mmHg), the AUC is as high as 0.83 (95% CI 0.76-0.90). The optimal echo derived PASP cutoff value to diagnose severely elevated pulmonary pressure was 58 mmHg (at the point of maximal Youden's index) with 0.75 sensitivity and 0.81 specificity (Figure 3b). Echocardiographic overestimation of PASP of more than 10mmHg was found in 35.0% of the patients, and underestimation was found in 11.6% of the patients (figure 4).

Finally, in a separate analysis of the patients with no TR jet and no PASP estimation, we found that mPAP measured by RHC was not different compared to those with measurable TR jet - 26.4 ± 11.5 mmHg versus 25.9 ± 11.5 mmHg. Factors associated with non-measurable TR jet were male gender (78.6% versus 61.8%) and overweight (mean BMI 28.3 ± 4.8 versus 25.93 ± 5.63) (supplementary Table 2).

Discussion

PH is a well-known sequelae of advanced lung disease. Its diagnosis in LT candidates is crucial for the decision about the optimal medical and surgical treatment. Current guidelines rely on the echocardiographic assessment of PASP and do not recommend routine RHC for the diagnosis of PH. Previous studies assessing the correlation between PASP assessment by echocardiography and RHC measurements in patients with a variety of cardiopulmonary disorders found a good correlation between the two methods with an r value of 0.65 to 0.97 by Pearson's correlation^{14,19-29}. Other trials suggest that the echocardiographic measurement of pulmonary hypertension might be inaccurate, with high rates of either under or over estimation of PASP^{10,14,30-32}. Moreover, some patients have no measurable tricuspid regurgitant jet, which makes the PASP estimation more challenging and often impossible¹¹.

Our study results confirms and expand upon previous observations with an updated analysis of a large group of LT candidates and accuracy analysis. Although the correlation between the echocardiographic estimation of PASP and the direct measurement of PASP by RHC was found to be moderate, the echocardiographic measurements were inaccurate and tended to overestimate the real PASP by more than 10mmHg in $\sim 1/3$ of the patients, and to underestimate it in more than $1/10$ of the patients.

There are a few possible explanations for the limited correlation between the two diagnostic methods. First, mistakes may occur in accurate measurement of the peak tricuspid regurgitation signal. Suboptimal Doppler alignment or poor quality of the Doppler signals may cause overestimation and underestimation of the PASP. Moreover, when calculating trans tricuspid pressure gradients using the Bernoulli equation, the TR velocity is squared and multiplied by 4, meaning that small errors in the TR velocity measurements can result in major changes in the pressure estimation. Second, in order to estimate PASP, the pressure gradients across the tricuspid valve needs to be added to the estimate RAP, the latter derived from IVC dimeter and it's collapsibility. However, in many patients, IVC diameter is difficult to obtain, and even in those where measurement is possible, the accuracy between echo estimation of RAP and invasive measurement is as low as 34%³³⁻³⁴.

The limited accuracy of the echocardiographic measurements, and its moderate correlation with the gold standard RHC derived PASP, suggest that in the unique population of LT candidates, routine RHC may be mandatory in the pre-surgical evaluation, regardless of the echocardiographic estimation of PASP.

Moreover, in the group of patients with non-measurable TR jet and no echocardiographic estimation of PASP (10.9% of the candidates) the mPAP on RHC was similar to those with measurable TR, meaning that the absence of TR does not predict absence of PH. This might be explained by technically difficult echocardiographic studies in those patients who were found to be obese compared to the group of patients with measurable TR. Regardless from the reason, results suggest that invasive measurements are also inevitable in the pre-surgical evaluation of patients with non-measurable TR jet.

Since the prediction value of echocardiography PASP measurements improved significantly when using it to diagnose severely elevated pulmonary pressure, we suggest using this noninvasive method as a reliable tool for follow up and assessment of treatment response when PASP estimation exceeds 58 mmHg.

The study has a few limitations: First, it is based on a retrospective cohort. The echocardiographic interpretation and RHC measurements were not supervised or reviewed by a second physician. Second, RHC related complications were not recorded. Nevertheless, to the best of our knowledge, this is the largest study of its kind which reflects the real-world data of LT candidates and their pre-surgical evaluation.

Conclusion

In the pre-surgical evaluation of LT candidates, echocardiographic estimation of PASP had moderate correlation with the PASP measured by RHC, and tended to overestimate or underestimate RHC measurements. Echocardiography PSAP measurements were moderately discriminative to diagnose PH. The absence of TR did not preclude elevated PASP. Based on the study results, we recommend performing routine RHC to all LT candidates, regardless of the echocardiographic estimation of PASP or the presence of TR gradient.

Declarations

Ethics approval - The study protocol and data collection was approved by Rabin Medical Center's human research committee, according to the ethical guidelines of the 1975 declaration of Helsinki.

Ethics and consent to participate: Since the data was collected retrospectively and anonymously, and according to ethical guidelines, patients consent was not required.

Consent for publication: Not applicable

Availability of data and materials: The data used and analyzed during the current study are available from the corresponding author on reasonable request.

Funding: none

Competing interest statement – The authors declare that they have no competing interests.

Authors contribution:

TA- Writing - original draft; **AL** - Methodology, Software; **DH** - Writing -review and editing; Supervision; **MRK** - Writing - review and editing; **TB** - Data curation; **TBA** - Methodology, Software; **AS** - Writing - review and editing; **AS** - Investigation; **HVA** - Investigation; **LP** - Investigation; **DR** - Visualization; **YS** - Visualization; **RK**- Supervision; **KS** - Conceptualization, Writing - original draft.

All authors have read and approved the manuscript.

Acknowledgments – Not applicable

References

1. Nathan SD, Barbera JA, Gaine SP, Harari S, Martinez FJ, Olschewski H, et al. Pulmonary hypertension in chronic lung disease and hypoxia. *Eur Respir J*. 2019;53(1).
2. Bonno EL, Viray MC, Jackson GR, Houston BA, Tedford RJ. Modern Right Heart Catheterization: Beyond Simple Hemodynamics. *Adv Pulm Hypertens*. 2020;19(1):6–15.
3. Merlo CA, Weiss ES, Orens JB, Borja MC, Diener-West M, Conte JV, et al. Impact of U.S. Lung Allocation Score on Survival After Lung Transplantation. *J Heart Lung Transplant*. 2009;28(8):7.
4. Members WC, McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation*. 2009;119(16):2250–94.
5. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
6. Whelan TPM, Dnitz JM, Kelly RF, Edwards LB, Herrington CS, Hertz MI, et al. Effect of Preoperative Pulmonary Artery Pressure on Early Survival After Lung Transplantation for Idiopathic Pulmonary Fibrosis. *J Heart Lung Transplant*. 2005 Sep;24(9):1269–74.
7. Shigemura N, Bhama J, Gries CJ, Kawamura T, Crespo M, Johnson B, et al. Lung transplantation in patients with prior cardiothoracic surgical procedures. *Am J Transplant*. 2012;12(5):1249–55.

8. Despotis GJ, Karanikolas M, Triantafillou AN, Pond CG, Kirvassilis GV, Patterson GA, et al. Pressure gradient across the pulmonary artery anastomosis during lung transplantation. *Ann Thorac Surg*. 1995;60(3):630–4.
9. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. :58.
10. Farber HW, Foreman AJ, Miller DP, McGoon MD. REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension. *Congest Heart Fail*. 2011;17(2):56–63.
11. McCrory DC, Coeytaux RR, Schmit KM, Kraft B, Kosinski AS, Mingo AM, et al. Pulmonary arterial hypertension: screening, management, and treatment. 2013;
12. Hoeper MM, Lee SH, Voswinckel R, Palazzini M, Jais X, Marinelli A, et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. *J Am Coll Cardiol*. 2006;48(12):2546–52.
13. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2018;5(3):G11–24.
14. Arcasoy SM, Christie JD, Ferrari VA, Sutton MSJ, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. *Am J Respir Crit Care Med*. 2003;167(5):735–40.
15. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. Elsevier; 2015.
16. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. *Am J Cardiol*. 1990 Aug 15;66(4):493–6.
17. Hatle L, Angelsen BA, Tromsdal A. Non-invasive estimation of pulmonary artery systolic pressure with Doppler ultrasound. *Heart*. 1981 Feb 1;45(2):157–65.
18. Bossone E, D’Andrea A, D’Alto M, Citro R, Argiento P, Ferrara F, et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. *J Am Soc Echocardiogr*. 2013;26(1):1–14.
19. D’Alto M, Romeo E, Argiento P, D’Andrea A, Vanderpool R, Correra A, et al. Accuracy and precision of echocardiography versus right heart catheterization for the assessment of pulmonary hypertension. *Int J Cardiol*. 2013;168(4):4058–62.
20. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. *Circulation*. 1984;70(4):657–62.

21. Rudski LG. Point: can Doppler echocardiography estimates of pulmonary artery systolic pressures be relied upon to accurately make the diagnosis of pulmonary hypertension? Yes. *Chest*. 2013;143(6):1533–6.
22. Currie PJ, Seward JB, Chan K-L, Fyfe DA, Hagler DJ, Mair DD, et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. *J Am Coll Cardiol*. 1985;6(4):750–6.
23. Ben-Dor I, Kramer MR, Raccah A, Iakobishvilli Z, Shitrit D, Sahar G, et al. Echocardiography versus right-sided heart catheterization among lung transplantation candidates. *Ann Thorac Surg*. 2006;81(3):1056–60.
24. Chan K-L, Currie PJ, Seward JB, Hagler DJ, Mair DD, Tajik AJ. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. *J Am Coll Cardiol*. 1987;9(3):549–54.
25. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. *J Am Coll Cardiol*. 1985;6(2):359–65.
26. Laaban J-P, Diebold B, Zelinski R, Lafay M, Raffoul H, Rochemaure J. Noninvasive estimation of systolic pulmonary artery pressure using Doppler echocardiography in patients with chronic obstructive pulmonary disease. *Chest*. 1989;96(6):1258–62.
27. Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. *Eur Heart J*. 1991;12(2):103–11.
28. Torbicki A, Skwarski K, Hawrylkiewicz I, Pasierski T, Miskiewicz Z, Zielinski J. Attempts at measuring pulmonary arterial pressure by means of Doppler echocardiography in patients with chronic lung disease. *Eur Respir J*. 1989;2(9):856–60.
29. Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. *Chest*. 2011;139(5):988–93.
30. Homma A, Anzueto A, Peters JL, Susanto I, Sako E, Zabalgoitia M, et al. Pulmonary artery systolic pressures estimated by echocardiogram vs cardiac catheterization in patients awaiting lung transplantation. *J Heart Lung Transplant*. 2001;20(8):833–9.
31. Testani JM, Sutton MGSJ, Wiegers SE, Khera AV, Shannon RP, Kirkpatrick JN. Accuracy of noninvasively determined pulmonary artery systolic pressure. *Am J Cardiol*. 2010;105(8):1192–7.
32. Fisher MR, Forfia PR, Chamera E, Houston-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. *Am J Respir Crit Care*

Med. 2009;179(7):615–21.

33. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. *Echo Res Pract*. 2018 Sep;5(3):G11–24.

34. Magnino C, Omedè P, Avenatti E, Presutti D, Iannaccone A, Chiarlo M, et al. Inaccuracy of Right Atrial Pressure Estimates Through Inferior Vena Cava Indices. *Am J Cardiol*. 2017 Nov 1;120(9):1667–73.

Figures

Figure 1

The correlation between PASP estimated by echocardiography to that measured by RHC.

Figure 2

The estimated PASP measured by echocardiography in patients with confirmed diagnosis of PH (RHC mPAP > 20 mmHg) and in patients with pulmonary normo-tension (RHC mPAP ≤ 20 mmHg)

Figure 3

a) A ROC curve demonstrating the prediction value of echocardiography to diagnose PH (mean PAP > 20 mmHg). AUC - 0.72; 95% confidence interval 0.66-0.77. The Youden index was found to be estimated PASP above 40 mmHg. This echocardiographic estimation results in 73% sensitivity and 59% specificity. b) A ROC curve demonstrating the prediction value of echocardiography to diagnose severe PH (mean PAP > 40 mmHg). AUC - 0.83; 95% confidence interval 0.76-0.90. The Youden index was found to be estimated PASP above 58 mmHg. This echocardiographic estimation results in 75% sensitivity and 81% specificity.

Figure 4

The Bland-Altman method was used to plot the difference in PASP measurements for each patient (RHC PASP measurement minus estimated PASP per echocardiogram) against the mean of the two measurements. The limits of agreement are indicated by the broken lines - that is, the interval of two standard deviation of the measurement differences either side of the mean difference.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarytable1.pdf](#)
- [SupplementaryTable2new.docx](#)